Statements (117)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:brand
gptkb:drug |
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Neurocrine_Biosciences
|
| gptkbp:activities |
dopamine D2 receptor partial agonist
serotonin 5-H T1 A receptor partial agonist serotonin 5-H T2 A receptor antagonist dopamine D3 and D2 receptor partial agonist serotonin 5-H T1 A receptor agonist |
| gptkbp:approves |
gptkb:2015
schizophrenia bipolar disorder |
| gptkbp:brand |
gptkb:cariprazine
|
| gptkbp:class |
atypical antipsychotic
|
| gptkbp:clinical_trial |
Phase III
acute episodes treatment of schizophrenia long-term management maintenance treatment of bipolar disorder treatment of manic or mixed episodes of bipolar disorder treatment of manic or mixed episodes treatment of depressive episodes in bipolar disorder |
| gptkbp:contraindication |
severe hepatic impairment
lactation severe cardiovascular disease hypersensitivity to cariprazine |
| gptkbp:developed_by |
gptkb:Abb_Vie
|
| gptkbp:dosage_form |
gptkb:beer
3 mg 1.5 mg 4.5 mg |
| gptkbp:duration |
short-term
long-term as prescribed by physician |
| gptkbp:effective_date |
2015-09-17
|
| gptkbp:form |
gptkb:beer
|
| gptkbp:formulation |
extended-release
|
| gptkbp:frequency |
once daily
|
| gptkbp:has_ability |
6 mg
3 mg 1.5 mg 4.5 mg |
| gptkbp:healthcare |
gptkb:battle
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vraylar
|
| gptkbp:ingredients |
gptkb:cariprazine
|
| gptkbp:interacts_with |
MAO inhibitors
CY P3 A4 inducers CY P3 A4 inhibitors |
| gptkbp:invention |
gptkb:Abb_Vie
2026-09-17 |
| gptkbp:is_monitored_by |
gptkb:weight
blood pressure blood glucose lipid levels |
| gptkbp:is_used_for |
schizophrenia
bipolar disorder treatment of schizophrenia treatment of bipolar disorder |
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Abb_Vie
|
| gptkbp:market |
gptkb:stock_market_index
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe Vraylar brand name |
| gptkbp:name |
not on WHO Essential Medicines List
|
| gptkbp:packaging |
blister pack
|
| gptkbp:population |
adults
adolescents |
| gptkbp:previous_name |
gptkb:battle
|
| gptkbp:price |
varies by region
|
| gptkbp:provides_information_on |
included in treatment guidelines
follow prescribing information consider patient history evaluate for metabolic syndrome |
| gptkbp:regulates |
gptkb:battle
|
| gptkbp:requires |
gptkb:theorem
available online prescription only |
| gptkbp:research |
ongoing
|
| gptkbp:research_focus |
safety profile
long-term efficacy comparative effectiveness |
| gptkbp:scholarships |
avoid alcohol
monitor for mood changes do not discontinue abruptly |
| gptkbp:side_effect |
anxiety
fatigue headache nausea weight loss metabolic syndrome seizures restlessness drowsiness insomnia cardiovascular events constipation dry mouth weight gain blurred vision sedation hyperlipidemia sexual dysfunction tachycardia agitation hyperglycemia extrapyramidal symptoms akathisia neuroleptic malignant syndrome tardive dyskinesia orthostatic hypotension elevated prolactin levels |
| gptkbp:storage |
room temperature
protected from light protected from moisture |